Study identifier:D6930L00001
ClinicalTrials.gov identifier:NCT06422689
EudraCT identifier:N/A
CTIS identifier:N/A
ANCHOR - Assessment of Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
asthma
Phase 4
No
Albuterol and budesonide inhalation aerosol
All
2000
Interventional
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
Premier HealthCare Solutions Inc.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Albuterol and budesonide inhalation aerosol Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period. | - |